On June 28, 2021, this Phase 1 clinical trial was terminated to enable the development of an enhanced version of the vaccine.

The purpose of this first-time-in-human (FTiH) Phase 1 study is to assess the reactogenicity, safety and immunogenicity of four different dose levels of an experimental herpes simplex virus type 2 (HSV-2) vaccine, when administered intramuscularly (IM) on a 0, 2-month schedule to 60 healthy participants aged 18-40 years.